Hyperlipidemia and inhibitors of HIV protease.
Curr Opin Clin Nutr Metab Care
; 4(2): 99-103, 2001 Mar.
Article
en En
| MEDLINE
| ID: mdl-11224652
ABSTRACT
HIV protease inhibitors have been successfully incorporated into therapy for patients with HIV. These otherwise efficacious treatments present with multiple metabolic side-effects and body habitus changes known as the lipodystrophy syndrome. Direct associations of the lipid abnormalities with protease inhibitor use have been described, and ongoing studies are focused on describing mechanisms for future intervention. Mechanisms based on the molecular identity of the protease inhibitor target with human proteins, interference with aspects critical to lipoprotein production, and interference with adipocyte differentiation have been described. This review highlights the complexities of this syndrome, and discusses putative mechanisms whereby protease inhibitors cause hyperlipidemia.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Infecciones por VIH
/
Inhibidores de la Proteasa del VIH
/
Hiperlipidemias
/
Lipodistrofia
Límite:
Humans
Idioma:
En
Revista:
Curr Opin Clin Nutr Metab Care
Asunto de la revista:
CIENCIAS DA NUTRICAO
/
METABOLISMO
Año:
2001
Tipo del documento:
Article
País de afiliación:
Estados Unidos